These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26648065)

  • 1. Drug Targets for Obesity and Depression: From Serotonin to Leptin.
    Haleem DJ
    Curr Drug Targets; 2016; 17(11):1282-91. PubMed ID: 26648065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leptin signaling as a therapeutic target of obesity.
    Sáinz N; González-Navarro CJ; Martínez JA; Moreno-Aliaga MJ
    Expert Opin Ther Targets; 2015 Jul; 19(7):893-909. PubMed ID: 25726860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targets for obesity pharmacotherapy.
    Aronne LJ; Thornton-Jones ZD
    Clin Pharmacol Ther; 2007 May; 81(5):748-52. PubMed ID: 17438540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin in depression: a potential therapeutic target.
    Ge T; Fan J; Yang W; Cui R; Li B
    Cell Death Dis; 2018 Oct; 9(11):1096. PubMed ID: 30367065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.
    Köhler S; Cierpinsky K; Kronenberg G; Adli M
    J Psychopharmacol; 2016 Jan; 30(1):13-22. PubMed ID: 26464458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonist as novel therapeutic intervention.
    Kurhe Y; Mahesh R
    Asian J Psychiatr; 2015 Oct; 17():3-9. PubMed ID: 26243683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and Mental Illness.
    Sestan-Pesa M; Horvath TL
    Trends Mol Med; 2016 Feb; 22(2):174-183. PubMed ID: 26776095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and investigational antiobesity agents and obesity therapeutic treatment targets.
    Bays HE
    Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission.
    Kurhe Y; Mahesh R
    Pharmacol Biochem Behav; 2015 Sep; 136():107-16. PubMed ID: 26188166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain somatic cross-talk: ghrelin, leptin and ultimate challengers of obesity.
    Popovic V; Duntas LH
    Nutr Neurosci; 2005 Feb; 8(1):1-5. PubMed ID: 15909762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The pharmacological treatment of obesity: past, present and future].
    Simonyi G; Pados G; Medvegy M; Bedros JR
    Orv Hetil; 2012 Mar; 153(10):363-73. PubMed ID: 22370224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novel therapeutic approach based on recent understanding of the development of metabolic syndrome].
    Hosoi T
    Yakugaku Zasshi; 2011; 131(11):1557-62. PubMed ID: 22041693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The regulation of body mass and its relation to the development of obesity].
    Juhász A; Katona E; Csongrádi E; Paragh G
    Orv Hetil; 2007 Sep; 148(39):1827-36. PubMed ID: 17890170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QCM-4, a 5-HT₃ receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice.
    Kurhe Y; Mahesh R; Devadoss T
    Biochem Biophys Res Commun; 2015 Jan; 456(1):74-9. PubMed ID: 25446100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of appetite suppression: implication for the treatment of obesity.
    Halford JC
    Curr Drug Targets; 2001 Dec; 2(4):353-70. PubMed ID: 11732637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The leptin hypothesis of depression: a potential link between mood disorders and obesity?
    Lu XY
    Curr Opin Pharmacol; 2007 Dec; 7(6):648-52. PubMed ID: 18032111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds.
    Tutone M; Lauria A; Almerico AM
    Curr Pharm Des; 2014; 20(1):136-45. PubMed ID: 24180400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin signaling, adiposity, and energy balance.
    Jéquier E
    Ann N Y Acad Sci; 2002 Jun; 967():379-88. PubMed ID: 12079865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.